Диссертация (1154700), страница 18
Текст из файла (страница 18)
— 1996. — Vol. 86. —P.858–862.213. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives / Ross RK, Pike MC, Vessey MP. [et al.] // Br Med J (Clin Res Ed). — 1986. —Vol. 293. — P.359–362.214. Sadan, O. Oestrogen and progesterone receptor concentrations in leiomyomaand normal myometrium / Sadan O., B. Van Iddekinge, C. J. Van Gelderen // Annals ofClinical Biochemistry.
— 1987. — Vol. 24. — №. 3. — Р. 263–267.215. Santos-Rebouqas, C.B. Implication of abnormal epigenetic patterns forhuman diseases / Santos-Rebouqas C.B., Pimentel M.M.G. // Eur. J. Hum. Genet. —2007. — Vol. 15. — P. 10-17.216. Schwartz, SM. Epidemiologic contributions to understanding the etiology ofuterine leiomyomata / Schwartz SM, Marshall LM, Baird DD. — 2000. — Vol. 108(Suppl 5). — Р.821–827.217. Shiota, K. Epigenetics by DNA methylation for development of normal andcloned animals /Shiota K, Yanagimachi R.
// Differentiation. — 2002. — Vol. 69. —Р.162–166.218. Silencing of tumor suppressor genes RASSF1A, SLIT2, and WIF1 bypromoter hypermethylation in hereditary breast cancer / Alvarez C. [et al.] // Mol.Carcinog. — 2013. — Vol. 52(6). — P.475-487.219. Structural basis of Wnt recognition by Frizzled. / Janda C.Y., Waghray D.,Levin A.M. [et al.] // Science. — 2012. — Vol. 337. — P.59–64.220. Submuoous fibroids: a new presurgical classiftcation to evaluate the viabilityof hydroscopic surgical treat ment preliminary report / Lasmar R.B., Barrozo P.R.,112Dias R., Oliveira M.A.
// J. Minim. Invasive Gynecol. — 2005. — Vol. 12. — P. 308–11.221. Tetsu, O. b-Catenin regulates expression of cyclin D1 in colon carcinoma cells/ Tetsu O, McCormick F. // Nature. — 1999. — Vol. 398. — P.422-426.222. The direct and indirect costs of uterine fibroid tumors: A systematic review ofthe literature between 2000 and 2013 / Soliman, A.M.; Yang, H.; Du, E.X.
[et al.] // Am.J. Obstet. Gynecol. — 2015. — Vol. 213. — P.141–160.223. The effect of a levonorgestrel-releasing intrauterine device in the treatment ofmyoma-related menorrhagia. / Mercorio F. [et al.] // Contraception. — 2003. — Vol. 67.— P.277-280.224. The estimated annual cost of uterine leiomyomata in the United States /Cardozo ER, Clark AD, Banks NK. [et al.] // Am. J. Obstet.
Gynecol. — 2012. —Vol. 206(3). — P.211.225. The extracellular matrix component WIF-1 is expressed during, and canmodulate, retinal development / Hunter DD, Zhang M, Ferguson JW. [et al.] // Mol. andCell. Neurosci. — 2004. — Vol. 27(4). — P.477-488.226. The FIGO systems for nomenclature and classification of causes of abnormaluterine bleeding in the reproductive years: who needs them? / Malcolm G. Munro, HilaryO.D. Critchley, Ian S.
Fraser // American Journal of Obstetrics & Gynecology. — 2012.– Р. 259–265.227. The Mechanism and Function of Epigenetics in Uterine LeiomyomaDevelopment // Qiwei Yang, Aymara Mas, Michael P. [et al.] // Reproductive Sciences. —P.1-13.228. The management of uterine leiomyomas / Vilos, G.A.; Allaire, C.; Laberge,P.Y. [et al.] // J.
Obstet. Gynaecol. Can. — 2015. — Vol. 37. — P.157–181.229. Tiltman, A. J. The effect of progestins on the mitotic activity of uterinebromyomas / Tiltman A. J. // International Journal of Gynecological Pathology. — 1985.— Vol. 4. — №2. — Р.89–96.230. Transformation by the simian virus 40 T antigen is regulated by IGF-I receptorand IRS-1 signaling / DeAngelis T, Chen J, Wu A. [et al.] // Oncogene. — 2006. —Vol. 25 — P.32–42.113231. Trends in the National Distribution of Laparoscopic Hysterectomies from2003–2010 / Lee J.; Jennings, K.; Borahay, M.A. [et al.] // J. Minim. Invasive Gynecol.— 2014.
— Vol. 21. — P.656–661.232. Twisted Subserosal Uterine Leiomyoma during Gonadotropin ReleasingHormone Agonist (GnRHa) Therapy / Yamasaki H., Otuka H., Fukuda M. [et al.] // J ofMinimally Invasive Gynecology. — 2012. — No 19. — P. 148–150.233. Two distinct estrogenregulated promoters generate transcripts encoding thetwo functionally different human progesterone receptor forms A and B / P. Kastner, A.Krust, B.
Turcotte [et al.] // The EMBO Journal. — 1990. — Vol. 9. — №. 5. — Р. 1603–1614.234. Ultrasound-Based Study to Evaluate Risk Factors for Uterine FibroidIncidence and Growth: Methods and Results of Recruitment / Baird, D.D.; Harmon, Q.E.;Upson, K. [et al.] // J. Women’s Health (Larchmt). — 2015. — Vol. 24 — P.907–915.235. Up-regulation by progesterone of proliferating cell nuclear antigen andepidermal growth factor expression in human uterine leiomyoma / Y. Shimomura,H. Matsuo, T. Samoto, T. Maruo // Journal of Clinical Endocrinology and Metabolism.— 1998. — Vol. 83. — №6. — Р. 2192–2198.236. Uterine fibroids and gynecologic pain symptoms in a population-based study /Lippman, S.A.; Warner, M.; Samuels, S.
[et al.] // Ferti Steril. — 2003 — Vol. 80 —P.1488–1494.237. Vanyushin, B.F. Epigenetics today and tomorrow / B.F. Vanyushin //Вавиловский журнал генетики и селекции. — 2013. — Том 17, № 4/2. — C. 805-831.238. Value of Magnetic Resonance Imaging in Diagnosis of Adenomyosis andMyomas of the Uterus / Charalampos P.S., Themistoklis M., Grigoris F.G.
[et al.] // J ofMinimally Invasive Gynecology. — 2012. — Vol. 19. — No5. — P. 620–626.239. Variation in the incidence of uterine leiomyoma among premenopausalwomen by age and race / Marshall LM, Spiegelman D, Barbieri RL. [et al.] // ObstetGynecol. — 1997. — Vol. 90. — P.967-973.240.
Varmus, H. Ten years on – The human genome and medicine / Varmus H. //New Engl. J. Med. —2010. — Vol. 362. — P. 2028–2029.114241. Verdone, L. Role of histone acetylation in the control of gene expression /Verdone L, Caserta M, DiMauro E. // Biochem Cell Biol. — 2005. — Vol. 83(3). —P.344-353.242. Wamsteker, K. Transcervical hysteroscopic resection of submucous fibroidsfor abnormal uterine bleeding: results regarding the degree of intramural extension /Wamsteker K., Emanuel M.H., de Kruif J.H. // Obstet. Gynecol.
— 1993. — Vol. 82(5). — P. 736–740.243. Wei, J. Expression profile of the tumorigenic factors associated with tumorsize and sex steroid hormone status in uterine leiomyomata / Wei J., Chiriboga L., MittalK. // Fertil. Steril. — 2005. — Vol. 84. — N2. — P. 474–484.244. Whitelaw, E. Sins of the fathers, and their fathers / Whitelaw E. // Eur. J. Hum.Genet. — 2006. — Vol. 14. — P. 131-132.245. Whitelaw, N.C.
How lifetimes shape epigenotype within and acrossgenerations / Whitelaw N.C, Whitelaw E. //Hum. Mol. Genet. — 2006. — Vol. 15. —P.131-137.246. Wif-1 is expressed at cartilage-mesenchyme interfaces and impedes Wnt3amediated inhibition of chondrogenesis / Surmann-Schmitt C, Widmann N, Dietz U. [etal.] // J. of Cell Science. — 2009.
— Vol. 122(20). — P.3627-3637.247. Wnt/beta-catenin signaling in development and disease. / Clevers H., Islam S,Protic O, [et al.] // Cell. — 2006 — Vol. 127(3). — P.469-480.248. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, andtargeted disruption accelerates osteosarcomagenesis in mice. / Kansara M, Tsang M,Kodjabachian L.[et al.] // J. of Clin. Invest. — 2009. — 119(4): 837-851249.
Wnt inhibitory factor-1 is silenced by promoter hypermethylation in humanlung cancer / Mazieres J., He B., You L.[et al.] //Cancer Res. — 2004. — Vol. 64. —№ 14. — P. 4717-4720.250. Weeraratna, AT. A Wnt-er wonderland -the complexity of Wnt signaling inmelanoma / Weeraratna AT. // Cancer Metastasis Rev. — 2005. — Vol. 24(2). — P.237250.251. Willert, K. Wnt Proteins / Willert K., Nusse R. // Cold Spring Harb. Lab.115Press.
— 2012. — №1. — 4(9).252. Wischnewski, F. Promoter demethylation and histone acetylation mediategene expression of MAGEA1, -A2, -A3, and -A12 in human cancer cells / WischnewskiF, Pantel K, Schwarzenbach H. // Mol Cancer Res. — 2006. — Vol. 4(5). — Р.339-349.253. World Health Organization Classification of Tumours: Pathology andGenetics of Tumours of the Breast and Female Genital Organs / Tavassoli F.A., Devilee P.[et al.]. — Lyon: IARC Press, 2003. — P.
236–243.254. Yingzi, Yang. Wnt signaling in development and disease / Yingzi Yang. // Cell& Bioscience. — 2012. — Vol. 2. — Р.14255. Ying, Z. Dual actions of progesterone on uterine leiomyoma correlate with theratio of progesterone receptor A:B / Ying Z., Z. Weiyuan // GynecologicalEndocrinology. — 2009. — Vol. 25. — №8. — Р.520–523.256. Zhang, Y. Patients' age, myoma size, myoma location, and interval betweenmyomectomy and pregnancy may influence the pregnancy rate and live birth rate aftermyomectomy / Zhang Y., Hua K.Q.
// J. Laparoendosc. Adv. Surg. Tech. A. — 2014. —Vol. 24(2). — Р.95-99..